RTP Mobile Logo
Oncology Grand Rounds: Part 1 — Lymphoma and Chronic Lymphocytic Leukemia
Released July 2018

Video proceedings from the first in a series of 6 integrated symposia held at the 2018 ONS Annual Congress. Featuring perspectives from Dr Ethan M Basch, Dr Andrew M Evens, Ms Amy Goodrich, Ms Robin Klebig and Dr Mitchell R Smith. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphoma and chronic lymphocytic leukemia (CLL).

    OVERVIEW OF ACTIVITY
    Taken together, it is estimated that approximately 174,250 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in 2018, and 58,100 individuals will die from these diseases. Of importance, nearly 70 drug products with more than 120 distinct FDA-approved indications are labeled for use in the management of hematologic cancers today. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate management strategies across a vast spectrum of liquid and solid tumors. This is particularly true within the realm of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL), where the past several years have seen substantial progress in the development and evaluation of novel agents. Mature clinical trial results have illustrated the efficacy of several new investigational therapies, a number of which have now entered the clinic, altering the therapeutic algorithms for HL and various subtypes of NHL. Furthermore, enthusiasm is widespread that additional advancements are on the horizon as other novel agents and strategies have already been associated with impressive clinical benefit.

    Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the first part of a 6-part integrated CNE curriculum originally held at the 2018 ONS Annual Congress feature discussions with leading lymphoma investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lymphomas and CLL.

    LEARNING OBJECTIVES

    • Provide patient-focused education to enhance clinical decision-making regarding available systemic agents used in the management of indolent and aggressive forms of B-cell NHL, including CLL, and HL.
    • Appreciate the contribution of patient performance status and comorbidities, biomarker profile and prior therapeutic exposure to the selection and sequence of systemic therapy for newly diagnosed and relapsed/refractory (R/R) CLL.
    • Review recent therapeutic advances in the management of newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and HL, and use this information to counsel patients regarding protocol and nonresearch options.
    • Formulate supportive care strategies to manage the side effects associated with recently approved therapeutic interventions for patients with HL, NHL and CLL.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    This educational activity for 2.7 contact hours is provided by RTP during the period of July 2018 through July 2019.

    ONCOLOGY NURSING CERTIFICATION CORPORATION (ONCC)/INDIVIDUAL LEARNING NEEDS ASSESSMENT (ILNA) CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. To review certification qualifications, please visit ResearchToPractice.com/ONS2018/ILNA.

    ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSLymphomas2018/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ethan M Basch, MD, MSc
    Professor of Medicine and Public Health
    Director, Cancer Outcomes Research Program
    Co-Leader, Cancer Prevention and Control
    Associate Chief, Division of Oncology
    University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina

    No relevant conflicts of interest to disclose.

    Andrew M Evens, DO, MSc
    Associate Director for Clinical Services
    Rutgers Cancer Institute of New Jersey
    Medical Director, Oncology Service Line
    RWJBarnabas Health
    Director, Lymphoma Program, Division of Blood Disorders
    Professor of Medicine
    Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey

    Advisory Committee: Novartis; Consulting Agreements: Merck, Novartis, Spectrum Pharmaceuticals Inc.

    Amy Goodrich, CRNP-AC
    Nurse Practitioner
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Advisory Committee and Speakers Bureau: Gilead Sciences Inc.

    Robin Klebig, APRN, CNP, AOCNP
    Division of Hematology, Lymphoma Group
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    Mitchell R Smith, MD, PhD
    Professor of Medicine
    Associate Center Director for Clinical Investigations
    Division of Hematology and Oncology
    GW Cancer Center
    Washington, DC

    Advisory Committee: Genentech BioOncology, Seattle Genetics; Contracted Research: Celgene Corporation, Takeda Oncology; Educational Presentation: AstraZeneca Pharmaceuticals LP.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: July 2018
    Expiration date: July 2019

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):